NZ724740A - Treatment of nafld and nash - Google Patents

Treatment of nafld and nash

Info

Publication number
NZ724740A
NZ724740A NZ72474015A NZ72474015A NZ724740A NZ 724740 A NZ724740 A NZ 724740A NZ 72474015 A NZ72474015 A NZ 72474015A NZ 72474015 A NZ72474015 A NZ 72474015A NZ 724740 A NZ724740 A NZ 724740A
Authority
NZ
New Zealand
Prior art keywords
nafld
nash
treatment
alcoholic
methylphenoxy
Prior art date
Application number
NZ72474015A
Other languages
English (en)
Inventor
Charles Mcwherter
Brian Roberts
Xueyan Wang
Yun-Jung Choi
David Karpf
Robert Martin
Original Assignee
Cymabay Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53373532&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ724740(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cymabay Therapeutics Inc filed Critical Cymabay Therapeutics Inc
Publication of NZ724740A publication Critical patent/NZ724740A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NZ72474015A 2014-04-11 2015-04-10 Treatment of nafld and nash NZ724740A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461978335P 2014-04-11 2014-04-11
PCT/US2015/025416 WO2015157697A1 (en) 2014-04-11 2015-04-10 Treatment of nafld and nash

Publications (1)

Publication Number Publication Date
NZ724740A true NZ724740A (en) 2019-11-29

Family

ID=53373532

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ72474015A NZ724740A (en) 2014-04-11 2015-04-10 Treatment of nafld and nash

Country Status (27)

Country Link
US (7) US9381181B2 (OSRAM)
EP (1) EP3129018B1 (OSRAM)
JP (1) JP6865038B2 (OSRAM)
KR (1) KR102374499B1 (OSRAM)
CN (1) CN106163508A (OSRAM)
AU (1) AU2015243239B2 (OSRAM)
BR (1) BR112016023269A8 (OSRAM)
CA (1) CA2944139C (OSRAM)
CL (1) CL2016002517A1 (OSRAM)
CY (1) CY1122602T1 (OSRAM)
DK (1) DK3129018T3 (OSRAM)
EA (1) EA036704B1 (OSRAM)
ES (1) ES2764467T3 (OSRAM)
HR (1) HRP20192299T1 (OSRAM)
IL (1) IL248193B (OSRAM)
LT (1) LT3129018T (OSRAM)
MX (1) MX369921B (OSRAM)
NZ (1) NZ724740A (OSRAM)
PH (1) PH12016501978B1 (OSRAM)
PL (1) PL3129018T3 (OSRAM)
PT (1) PT3129018T (OSRAM)
RS (1) RS59637B1 (OSRAM)
SG (1) SG11201608077PA (OSRAM)
SI (1) SI3129018T1 (OSRAM)
SM (1) SMT202000019T1 (OSRAM)
UA (1) UA121208C2 (OSRAM)
WO (1) WO2015157697A1 (OSRAM)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110236476A1 (en) 2008-09-02 2011-09-29 Amarin Corporation Plc. Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
MX2011004077A (es) 2008-10-17 2011-08-17 Metabolex Inc Metodos para reducir particulas de ldl densas, pequeñas.
SG10201605794PA (en) 2009-04-29 2016-09-29 Amarin Pharmaceuticals Ie Ltd Stable Pharmaceutical Composition And Methods Of Using Same
WO2010127099A2 (en) 2009-04-29 2010-11-04 Amarin Corporation Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
CN108096209A (zh) 2009-06-15 2018-06-01 阿马里纳制药公司 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法
WO2011038122A1 (en) 2009-09-23 2011-03-31 Amarin Corporation Plc Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
US9719068B2 (en) 2010-05-06 2017-08-01 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
EP2646013A4 (en) 2010-11-29 2014-03-26 Amarin Pharma Inc Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2775837A4 (en) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd METHODS OF TREATING HYPERTRIGLYCERIDEMIA
JP6307442B2 (ja) 2012-01-06 2018-04-04 アマリン ファーマシューティカルス アイルランド リミテッド 対象の高感度（ｈｓ−ｃｒｐ）のレベルを低下させる組成物および方法
SMT202500326T1 (it) 2012-06-29 2025-11-10 Amarin Pharmaceuticals Ie Ltd Estere etilico dell’acido eicosapentaenoico per l’uso nella riduzione del rischio di ictus non fatale in un soggetto in terapia con statine
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) * 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
CN106102734B (zh) 2014-03-20 2019-05-14 西玛贝医药公司 肝内胆汁淤积性疾病的治疗
KR102374499B1 (ko) 2014-04-11 2022-03-14 사이머베이 쎄라퓨틱스, 인코퍼레이티드 Nafld 및 nash 의 치료
US10174289B2 (en) 2014-05-28 2019-01-08 Children's Hospital Medical Center Methods and systems for converting precursor cells into gastric tissues through directed differentiation
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US11584916B2 (en) 2014-10-17 2023-02-21 Children's Hospital Medical Center Method of making in vivo human small intestine organoids from pluripotent stem cells
MX2017012319A (es) * 2015-03-26 2018-05-11 T3D Therapeutics Inc Metodos para tratar enfermedad hepática utilizando derivados de acido indano acético.
CN115025079A (zh) 2015-04-28 2022-09-09 普罗诺瓦生物医药挪威公司 结构增强的含硫脂肪酸在预防和/或治疗非酒精性脂肪性肝炎中的用途
WO2017049157A1 (en) * 2015-09-18 2017-03-23 Duke University Methods and compositions for the treatment of steatosis-associated disorders
WO2017139708A1 (en) 2016-02-10 2017-08-17 Synlogic, Inc. Bacteria engineered to treat nonalcoholic steatohepatitis (nash)
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US12053445B2 (en) 2016-03-31 2024-08-06 Genfit Methods of treatment of cholestatic diseases
CA3016641A1 (en) 2016-05-05 2017-11-09 Children's Hospital Medical Center Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
GB201614455D0 (en) * 2016-08-24 2016-10-05 Univ Oxford Innovation Ltd Biomarkers
KR102546194B1 (ko) * 2016-11-04 2023-06-21 칠드런즈 호스피탈 메디칼 센터 간 유사 장기 조성물 및 이를 제조 및 사용하는 방법
US10493363B2 (en) * 2016-11-09 2019-12-03 Activision Publishing, Inc. Reality-based video game elements
WO2018106628A1 (en) 2016-12-05 2018-06-14 Children's Hospital Medical Center Colonic organoids and methods of making and using same
WO2018191673A1 (en) 2017-04-14 2018-10-18 Children's Hospital Medical Center Multi donor stem cell compositions and methods of making same
WO2018204775A1 (en) 2017-05-05 2018-11-08 Hepanova, Inc. Amino-aryl-benzamide compounds and methods of use thereof
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
JP2020533339A (ja) 2017-09-13 2020-11-19 ノバルティス アーゲー Ｆｘｒアゴニストを含む組合せ
EP3694603A4 (en) 2017-10-10 2021-07-14 Children's Hospital Medical Center ESOPHAGUS TISSUE AND / OR ORGANOID COMPOSITIONS AND METHOD FOR MANUFACTURING THEREOF
US11260066B2 (en) 2017-10-27 2022-03-01 Samyang Corporation Inhibiting reduction of lean body mass and inhibiting accumulation of liver fat by administering allulose
SG11202005007VA (en) 2017-12-06 2020-06-29 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis
WO2019126626A1 (en) 2017-12-21 2019-06-27 Children's Hospital Medical Center Digitalized human organoids and methods of using same
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
WO2020023245A1 (en) 2018-07-26 2020-01-30 Children's Hospital Medical Center Hepato-biliary-pancreatic tissues and methods of making same
SG11202102431YA (en) 2018-09-12 2021-04-29 Childrens Hospital Med Ct Organoid compositions for the production of hematopoietic stem cells and derivatives thereof
EP3700518A4 (en) 2018-09-24 2020-12-16 Amarin Pharmaceuticals Ireland Limited METHODS OF REDUCING THE RISK OF CARDIOVASCULAR EVENTS IN A SUBJECT
BR112021009038A2 (pt) * 2018-11-16 2021-08-10 Cymabay Therapeutics, Inc. tratamento combinado de nafld e nash
EP3880187A1 (en) 2018-11-16 2021-09-22 CymaBay Therapeutics, Inc. Treatment of obesity and its complications
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
CA3141814A1 (en) 2019-05-31 2020-12-03 Children's Hospital Medical Center Shaped organoid compositions and methods of making same
EP3976066A4 (en) 2019-05-31 2023-06-28 Children's Hospital Medical Center Methods of generating and expanding hematopoietic stem cells
EP4017875A4 (en) 2019-08-23 2023-05-03 Terns Pharmaceuticals, Inc. THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS
JP2022548250A (ja) 2019-09-12 2022-11-17 ターンズ・ファーマシューティカルズ・インコーポレイテッド 甲状腺ホルモン受容体ベータアゴニスト化合物
CN114980973A (zh) 2019-11-12 2022-08-30 阿马里纳药物爱尔兰有限公司 降低心房纤颤和/或心房扑动受试者心血管事件风险的方法
WO2021097034A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Seladelpar for use in the treatment of intestinal barrier dysfunction and associated diseases
WO2021097027A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Seladelpar for use in the treatment of alcoholic liver disease
US20210379043A1 (en) * 2020-05-13 2021-12-09 Terns Pharmaceuticals, Inc. Combination treatment of liver disorders
EP4326244A4 (en) 2021-04-21 2025-03-19 Amarin Pharmaceuticals Ireland Limited METHODS TO REDUCE THE RISK OF HEART FAILURE
US20240216312A1 (en) * 2021-05-11 2024-07-04 Genfit Ppar-agonists for use in the treatment of liver failure

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
JPH10512894A (ja) 1995-03-06 1998-12-08 アイシス・ファーマシューティカルス・インコーポレーテッド ２’−ｏ−置換ピリミジンおよびそのオリゴマー化合物の合成の改良法
EP0882061B1 (en) 1996-02-14 2004-05-19 Isis Pharmaceuticals, Inc. Sugar-modified gapped oligonucleotides
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
DK1667964T3 (da) 2003-09-19 2009-10-26 Janssen Pharmaceutica Nv 4-((Phenoxyalkyl)thio)-phenoxyeddikesyrer og analoger
CA2910191C (en) 2004-03-05 2022-03-08 The Trustees Of The Univeristy Of Pennsylvania The use of mtp inhibitors for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
US20080176861A1 (en) 2007-01-23 2008-07-24 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis
MX2011004077A (es) 2008-10-17 2011-08-17 Metabolex Inc Metodos para reducir particulas de ldl densas, pequeñas.
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
JP2017505285A (ja) 2013-11-20 2017-02-16 サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ホモ接合性家族性高コレステロール血症の治療
CN106102734B (zh) 2014-03-20 2019-05-14 西玛贝医药公司 肝内胆汁淤积性疾病的治疗
KR102374499B1 (ko) * 2014-04-11 2022-03-14 사이머베이 쎄라퓨틱스, 인코퍼레이티드 Nafld 및 nash 의 치료
JP2017519028A (ja) 2014-06-26 2017-07-13 サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 重度の高トリグリセリド血症の処置

Also Published As

Publication number Publication date
ES2764467T3 (es) 2020-06-03
DK3129018T3 (da) 2020-01-20
US20190142776A1 (en) 2019-05-16
PL3129018T3 (pl) 2020-05-18
US20180008566A1 (en) 2018-01-11
CY1122602T1 (el) 2021-03-12
US10188620B2 (en) 2019-01-29
PH12016501978B1 (en) 2023-07-12
US20180228752A1 (en) 2018-08-16
BR112016023269A8 (pt) 2021-06-29
US9381181B2 (en) 2016-07-05
MX369921B (es) 2019-11-26
PH12016501978A1 (en) 2016-12-19
JP2017513836A (ja) 2017-06-01
SMT202000019T1 (it) 2020-03-13
WO2015157697A1 (en) 2015-10-15
RS59637B1 (sr) 2020-01-31
US20150290154A1 (en) 2015-10-15
EA201692050A1 (ru) 2017-01-30
IL248193B (en) 2019-03-31
US11179359B2 (en) 2021-11-23
AU2015243239A1 (en) 2016-10-20
EP3129018A1 (en) 2017-02-15
US10722483B2 (en) 2020-07-28
US10342770B2 (en) 2019-07-09
PT3129018T (pt) 2020-01-15
KR102374499B1 (ko) 2022-03-14
CA2944139A1 (en) 2015-10-15
KR20160136451A (ko) 2016-11-29
CN106163508A (zh) 2016-11-23
MX2016013375A (es) 2017-02-15
BR112016023269A2 (pt) 2017-08-15
US20160324812A1 (en) 2016-11-10
CA2944139C (en) 2020-11-03
US20210038546A1 (en) 2021-02-11
SG11201608077PA (en) 2016-10-28
UA121208C2 (uk) 2020-04-27
EP3129018B1 (en) 2019-10-23
HRP20192299T1 (hr) 2020-03-06
AU2015243239B2 (en) 2019-11-14
SI3129018T1 (sl) 2020-02-28
JP6865038B2 (ja) 2021-04-28
CL2016002517A1 (es) 2017-05-05
LT3129018T (lt) 2020-01-10
US9616039B2 (en) 2017-04-11
US9962346B2 (en) 2018-05-08
EA036704B1 (ru) 2020-12-10
US20200009092A1 (en) 2020-01-09

Similar Documents

Publication Publication Date Title
NZ724740A (en) Treatment of nafld and nash
IL275002A (en) Fatty acid antecedents for the treatment of nonalcoholic fatty liver disease
MX360979B (es) Composiciones de galacto-ramnogalacturonato para el tratamiento de la esteatohepatitis no alcohólica y de la enfermedad del higado graso no alcohólico.
NZ724057A (en) Treatment of intrahepatic cholestatic diseases
HK1249508A1 (zh) 氯喹和克立咪唑化合物用於治疗炎症和癌性病症的用途
EP3183005A4 (en) Methods and compositions for the treatment of metabolic disorders
MX2017009417A (es) Formas solidas de acido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido )acetico, composiciones y usos de las mismas.
NZ709803A (en) Compositions comprising 15-ohepa and methods of using the same
EP3207928A4 (en) Composite preparation, containing novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative and another active ingredient, for preventing or treating metabolic diseases
AU2017258781A1 (en) Di-substituted pyrazole compounds for the treatment of diseases
MX2016010447A (es) Composiciones y metodos para tratar diabetes y enfermedades hepáticas.
EA201790315A1 (ru) Модуляторы x-рецепторов печени
WO2016057658A8 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
EP3362053A4 (en) TREATMENT OF NON-ALCOHOLIC FATTYLENE OR NON-ALCOHOLIC STEATOHEPATITIS WITH 6-MERCAPTOPURIN WITH DELAYED RELEASE
EP3119387A4 (en) Compositions for the treatment of dermatological diseases and disorders
EP3203995A4 (en) COMPOSITIONS AND METHODS OF DELIVERING THERAPY AGENTS
MX2019002579A (es) Composiciones y metodos de uso de depuradores de gamma-cetoaldehido para tratar, evitar o mejorar la enfermedad del higado graso no alcoholico (nafld), nash, ald o condiciones relacionadas al higado.
EP3119388A4 (en) Carboxy-cyclopropyl undecanol compounds for treatment of liver disease and other medical disorders
IL274747A (en) FXR agonists for the treatment of liver diseases
EP3182952A4 (en) Modifying humidity to glabrous tissue for the treatment of migraine and other conditions
PT3475425T (pt) Tratamentos de esteato-hepatite não-alcoólica (nash)
RU2014145029A (ru) Способ профилактики рака печени и пищевода у лабораторных животных
HK40027618A (en) Fxr agonists for the treatment of liver diseases
EP3094330A4 (en) Treatment of crohn's disease using low doses of laquinimod
HK40012852A (en) Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 APR 2021 BY CPA GLOBAL

Effective date: 20200306

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 APR 2022 BY CPA GLOBAL

Effective date: 20210305

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 APR 2023 BY CPA GLOBAL

Effective date: 20220304

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 APR 2024 BY CPA GLOBAL

Effective date: 20230303

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 APR 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20240301

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 APR 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20250307